Contractor
DUKE UNIVERSITY
- UEI
- TP7EK8DZV6N5
- Parent UEI
- TP7EK8DZV6N5
- Resolved by
- uei
- Confidence
- 1.000
Active from Jun 20, 2019 to Aug 5, 2026.
Recent awards
| Award | Agency | Place | First action | Current value |
|---|---|---|---|---|
| 75R60220C00008 NATIONAL CORD BLOOD INVENTORY | Department of Health and Human Services | NC | Jul 10, 2020 | $31,016,848 |
| 75N93019C00015 IGF::OT::IGF NIAID VIROLOGY QUALITY ASSURANCE (VQA) | Department of Health and Human Services | NC | Jun 20, 2019 | $24,039,432 |
| 75N93019C00050 THIS CONTRACT WILL SUPPORT COMPONENT A OF THE COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) PROGRAM TO DESIGN AND EVALUATE INNOVATIVE INFLUENZA VACCINE APPROACHES, BASED ON PRINCIPLES OF INFLUENZA IMMUNITY, THAT ACHIEVE DURABLE, ROBUST | Department of Health and Human Services | NC | Sep 5, 2019 | $68,179,178 |
| 75F40123C00209 A STUDY IN MEDICARE ADVANTAGE FOR REAL WORLD EVIDENCE IN CARDIOVASCULAR DISEASE | Department of Health and Human Services | MD | Sep 28, 2023 | $1,567,108 |
| HHSN272201700061C TO ADMINISTRATE DE-OBLIGATE UNEXPENDED AND EXPIRING FISCAL YEAR 2021 FUNDING IN ACCORDANCE WITH 31 U.S.C. SECTION 1552 (A), IN PREPARATION FOR SEPTEMBER 30, 2026, CLOSING OF THE PERIOD OF AVAILABILITY OF THESE FISCAL YEAR FUNDS. | Department of Health and Human Services | NC | Jul 24, 2026 | $35,846,627 |
| 75N93022C00055 "ADVANCED DEVELOPMENT OF A NEUTRALIZING ANTIBODY VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES" | Department of Health and Human Services | NC | May 29, 2026 | $18,205,751 |
| 75N93022D00019 EO 14398 - EARLY PHASE CLINICAL TRIAL UNITS (EPCTU) | Department of Health and Human Services | — | Jul 21, 2026 | — |
| 80NSSC26P1049 LIGHTNING ADVISORY PANEL (LAP) AND FURTHER DEVELOPMENT AND EVALUATION OF THE LIGHTNING LAUNCH COMMIT CRITERIA (LLCC) | National Aeronautics and Space Administration | NC | Jul 20, 2026 | $36,193 |
| 75N93025C00006 NONHUMAN PRIMATE CORE HUMORAL IMMUNOLOGY LABORATORY FOR AIDS VACCINE RESEARCH AND DEVELOPMENT | Department of Health and Human Services | NC | Mar 13, 2026 | $5,120,519 |
| 75N94025D00003 EO 14398 NICHD: R&D: BEST PHARMACEUTICALS FOR CHILDREN ACT (BPCA) PEDIATRIC TRIALS NETWORK (PTN): NON-SEVERABLE | Department of Health and Human Services | — | Jul 16, 2026 | — |
| 140D0422P0227 NATIONAL DATA ARCHIVE ON CHILD ABUSE AND NEGLECT (NDACAN) OPERATION AND MAINTENANCE SERVICES | Department of the Interior | NC | Apr 21, 2026 | $5,063,966 |
| 75N93024C00074 INNOVATIONS IN FUNCTIONAL B CELL EPITOPE DISCOVERY | Department of Health and Human Services | NC | May 19, 2026 | $4,602,385 |
| 80NSSC26P0146 ENGAGING FOR-PROFIT ENTITIES IN A PRE-COMPETITIVE FRAMEWORK FOR TRUST-BUILDING, INNOVATION, AND MARKET INTELLIGENCE IN THE UTILITY SECTOR TARGETING RISK-AWARE INDUSTRIES IN PARTICULAR, THE INSURANCE SECTOR. | National Aeronautics and Space Administration | NC | Jul 15, 2026 | $75,000 |
| 75F40120C00179 QUANTIFYING PATIENTS' BENEFIT-RISK TRADEOFFS ASSOCIATED WITH PERCUTANEOUS REVASCULARIZATION OPTIONS FOR PERIPHERAL ARTERIAL DISEASE: A COLLABORATIVE EFFORT WITH THE RAPID PATHWAYS PATIENT SCIENCE WORKING GROUP | Department of Health and Human Services | NC | Jul 12, 2026 | $1,439,896 |
| 75N93022C00053 ADJUVANT COMPARISON AND CHARACTERIZATION | Department of Health and Human Services | NC | Apr 29, 2026 | $8,457,032 |
| 75N93022D00003 EO 14398 PRECLINICAL AND TRANSLATIONAL VACCINE DEVELOPMENT SUPPORT FOR HIV AND OTHER CANDIDATE AGENTS | Department of Health and Human Services | — | Jul 10, 2026 | — |
| 75N93024D00003 EXTERNAL QUALITY ASSURANCE PROGRAM OVERSIGHT LABORATORY (EQAPOL) | Department of Health and Human Services | — | Aug 26, 2024 | — |
| 75N93025C00002 EO 14398, RFO, INV, NON-COMMERCIAL BOT | Department of Health and Human Services | NC | Jul 9, 2026 | $1,876,865 |
| 75N93024C00005 EO 14398, RFO, INV, NON-COMMERCIAL BOT | Department of Health and Human Services | NC | Jul 9, 2026 | $3,499,087 |
| 36C24623P1586 BRAIN TISSUE PROCESSING WITH DUKE UNIVERSITY-MODIFICATION IMPLEMENTING EO 14398 | Department of Veterans Affairs | NC | Jul 1, 2026 | $1,712,544 |
| 75D30124F00003 CISA RSV INFANTS STUDY (LEAD SITE) | Department of Health and Human Services | NC | Jun 25, 2026 | $1,532,778 |
| 75D30123F00001 CISA CLINICAL VACCINE SAFETY EVALUATION; CUSTOMER INFORMATION TECHNOLOGY SUPPORT (CITS) EO 14398 | Department of Health and Human Services | NC | Jun 25, 2026 | $537,394 |
| 75N93024F00001 FEASIBILITY FOR DEVELOPMENT OF A LIPOSOME/LNP DISPLAYING AN HIV ENV TRIMER PROTEIN AND CONTAINING/INCORPORATING AN MRNA | Department of Health and Human Services | NC | Jun 17, 2026 | $5,885,384 |
| HHSN272201800004C NONHUMAN PRIMATE CORE HUMORAL IMMUNOLOGY LABORATORY FOR AIDS VACCINE RESEARCH AND DEVELOPMENT | Department of Health and Human Services | NC | Jun 17, 2026 | $17,977,570 |
| 75N93024F00001 EO 14398 | Department of Health and Human Services | NC | Jun 9, 2026 | $12,075,641 |
Sources and method
Figures on this page are computed from public federal award records. Numbers are never estimated or generated; where a figure is withheld, the reason is stated rather than filled in.
Totals sum obligations across every award attributed to this contractor. Obligations are cumulative funding actions, not the value of work delivered.
- 1Awards are attributed by Unique Entity Identifier TP7EK8DZV6N5, the government's own recipient identifier, not by name matching.
- 2Award records from USAspending.gov, last refreshed Aug 10, 2026.